Developing ASIC1-targeted therapeutics for ischemic injury

Advancing differentiated peptide, small-molecule, and formulation-based programmes enabled by FRDT
Explore our pipeline

From mechanism to therapeutic programmes

Approach

From ASIC1 biology to a differentiated multi-asset pipeline enabled by FRDT

Why YATREX

Mechanism

Targeting ASIC1-mediated injury pathways with strong translational rationale.

A multi-modal pipeline spanning polycyclic peptides, formulation-enabled repurposing, and small molecules.

Differentation

Execution

Preclinical programmes supported by defined pharmacokinetic and efficacy development plans.

  • YATRX-111 — Polycyclic peptide (Preclinical)
  • YATRX-203 — Formulation-enabled repurposing programme (Preclinical)
  • YATRX-305 — Optimised small-molecule programme (Preclinical)

Pipeline

Partner with us
Partner with us